Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
ADAM17 is upregulated in many cancers and in turn activates signaling pathways, including EGFR/ErbB, as well as those underlying resistance to targeted anti-EGFR therapies. Due to its central role in oncogenic pathways and drug resistance mechanisms, specific and efficacious monoclonal antibodies ag...
Enregistré dans:
Auteurs principaux: | , , , , , , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2022
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/0c1537a2f183403bbaf393d83c36b312 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|